Original Communication| Volume 154, ISSUE 3, P528-535, September 2013

Download started.


Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases

Published:April 18, 2013DOI:


      No standard treatment for advanced rectal cancer with synchronous resectable liver metastases (LM) has been defined. Radiochemotherapy prior to simultaneous or staged curative resection of both primary tumor and LM is one of the treatment options available. The response of LM to radiochemotherapy has never been evaluated and, in particular, the risk for progression of LM is unknown.


      Between 2000 and 2011, 20 patients underwent preoperative radiochemotherapy for advanced rectal cancer with synchronous limited but resectable LM. Imaging responses of LM to radiochemotherapy were analyzed on per-patient and per-lesion bases using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.


      Of the patients, 20 had 41 LM; 15 of the 20 patients (75%) had rectal cancer with expected circumferential margins <1 mm on magnetic resonance imaging (MRI), and 50% had a solitary LM before treatment. Of the patients, 13 received oxaliplatin-based chemotherapy, and 7 received fluorouracil (FU)-based chemotherapy in combination with radiation. Of the 41 LM, 7 showed complete response (17%); 7 showed partial response (17%); 20 remained stable (49%); and 7 progressed (17%). Of the 25 LM treated with oxaliplatin-based chemotherapy, only 1 LM (4%) progressed. All 20 patients were suitable for resection of LM with curative intent after the radiochemotherapy.


      In patients with advanced rectal cancer and synchronous limited, but resectable LM, the risk for progression of LM during radiochemotherapy is low, especially if the chemotherapy regimen contains oxaliplatin. This low risk does not compromise a curative surgical approach to LM.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • McMillan D.C.
        • McArdle C.S.
        Epidemiology of colorectal liver metastases.
        Surg Oncol. 2007; 16: 3-5
        • Bosset J.F.
        • Collette L.
        • Calais G.
        • Mineur L.
        • Maingon P.
        • Radosevic-Jelic L.
        • et al.
        Chemotherapy with preoperative radiotherapy in rectal cancer.
        N Engl J Med. 2006; 355: 1114-1123
        • Gérard J.P.
        • Conroy T.
        • Bonnetain F.
        • Bouché O.
        • Chapet O.
        • Closon-Dejardin M.T.
        • et al.
        Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
        J Clin Oncol. 2006; 24: 4620-4625
        • Sauer R.
        • Becker H.
        • Hohenberger W.
        • Rödel C.
        • Wittekind C.
        • Fietkau R.
        • et al.
        Preoperative versus postoperative chemoradiotherapy for rectal cancer.
        N Engl J Med. 2004; 351: 1731-1740
        • Nordlinger B.
        • Sorbye H.
        • Glimelius B.
        • Poston G.J.
        • Schlag P.M.
        • Rougier P.
        • et al.
        Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
        Lancet. 2008; 371: 1007-1016
        • Benoist S.
        [Recommendations for clinical pice. Therapeutic choices for rectal cancer. How should rectal cancers with synchronous metastases be managed?].
        Gastroenterol Clin Biol. 2007; 1: S75-S80
        • Roman S.
        • Cenni J.C.
        • Roy P.
        • Pujol B.
        • Napoleon B.
        • Keriven-Souquet O.
        • et al.
        Value of rectal ultrasound in predicting staging and outcome in patients with rectal adenocarcinoma.
        Dis Colon Rectum. 2004; 47: 1323-1330
        • Gérard J.P.
        • Azria D.
        • Gourgou-Bourgade S.
        • Martel-Laffay I.
        • Hennequin C.
        • Etienne P.L.
        • et al.
        Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
        J Clin Oncol. 2010; 28: 1638-1644
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • Wanders J.
        • Kaplan R.S.
        • Rubinstein L.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Heald R.J.
        • Ryall R.D.
        Recurrence and survival after total mesorectal excision for rectal cancer.
        Lancet. 1986; 1: 1479-1482
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213
        • Nagtegaal I.D.
        • van de Velde C.J.
        • van der Worp E.
        • Kapiteijn E.
        • Quirke P.
        • van Krieken J.H.
        Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control.
        J Clin Oncol. 2002; 20: 1729-1734
        • Rödel C.
        • Martus P.
        • Papadoupolos T.
        • Füzesi L.
        • Klimpfinger M.
        • Fietkau R.
        • et al.
        Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
        J Clin Oncol. 2005; 23: 8688-8696
        • Blazer 3rd, D.G.
        • Kishi Y.
        • Maru D.M.
        • Kopetz S.
        • Chun Y.S.
        • Overman M.J.
        • et al.
        Pathological response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
        J Clin Oncol. 2008; 26: 5344-5351
        • de Gramont A.
        • Figer A.
        • Seymour M.
        • Homerin M.
        • Hmissi A.
        • Cassidy J.
        • et al.
        Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
        J Clin Oncol. 2000; 18: 2938-2947
        • Auer R.C.
        • White R.R.
        • Kemeny N.E.
        • Schwartz L.H.
        • Shia J.
        • Blumgart L.H.
        • et al.
        Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.
        Cancer. 2010; 116: 1502-1509
        • Angliviel B.
        • Benoist S.
        • Penna C.
        • El Hajjam M.
        • Chagnon S.
        • Julié C.
        • et al.
        Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases.
        Ann Surg Oncol. 2009; 16: 1247-1253
        • Aschele C.
        • Cionini L.
        • Lonardi S.
        • Pinto C.
        • Cordio S.
        • Rosati G.
        • et al.
        Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
        J Clin Oncol. 2011; 29: 2773-2780
        • Rödel C.
        • Liersch T.
        • Becker H.
        • Fietkau R.
        • Hohenberger W.
        • Hothorn T.
        • et al.
        Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
        Lancet Oncol. 2012; 13: 679-687
        • Gosens M.J.
        • Klaassen R.A.
        • Tan-Go I.
        • Rutten H.J.
        • Martijn H.
        • van den Brule A.J.
        • et al.
        Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma.
        Clin Cancer Res. 2007; 13: 6617-6623
        • Wieser M.
        • Sauerland S.
        • Arnold D.
        • Schmiegel W.
        • Reinacher-Schick A.
        Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: a systematic review and meta-analysis of randomized trials.
        BMC Cancer. 2010; 10: 309
        • Gruenberger B.
        • Scheithauer W.
        • Punzengruber R.
        • Zielinski C.
        • Tamandl D.
        • Gruenberger T.
        Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
        BMC Cancer. 2008; 8: 120
        • Mentha G.
        • Majno P.E.
        • Andres A.
        • Rubbia-Brandt L.
        • Morel P.
        • Roth A.D.
        Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary.
        Br J Surg. 2006; 93: 872-878
        • Brouquet A.
        • Mortenson M.M.
        • Vauthey J.N.
        • Rodriguez-Bigas M.A.
        • Overman M.J.
        • Chang G.J.
        • et al.
        Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?.
        J Am Coll Surg. 2010; 210: 934-941
        • van der Pool A.E.
        • de Wilt J.H.
        • Lalmahomed Z.S.
        • Eggermont A.M.
        • Ijzermans J.N.
        • Verhoef C.
        Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases.
        Br J Surg. 2010; 97: 383-390
        • Fernández-Martos C.
        • Pericay C.
        • Aparicio J.
        • Salud A.
        • Safont M.
        • Massuti B.
        • et al.
        Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 Study.
        J Clin Oncol. 2010; 28: 859-865
        • Chua Y.J.
        • Barbachano Y.
        • Cunningham D.
        • Oates J.R.
        • Brown G.
        • Wotherspoon A.
        • et al.
        Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
        Lancet Oncol. 2010; 11: 241-248